Aphria says its Australian-based partner Althea Company Pty Ltd has been granted a Manufacture Licence by the Australian Government’s Office of Drug Control.
The license provides Althea with authorization to manufacture extracts and tinctures of cannabis and cannabis resin in accordance with relevant manufacture permits.
“This is another step towards ensuring Australian patients have access to high-quality medicinal cannabis,” said Vic Neufeld, CEO of Aphria.
“Coupled with the existing Medicinal Cannabis Licence, Althea can now proceed with the next phase of planning for our Victorian-based production facility,” said Althea CEO Josh Fegan.
“Patients approved for Althea medicinal cannabis products have quickly passed the recent 100 patient milestone, with 127 patients now approved,” he said.
“Similarly, the number of doctors prescribing Althea products has increased from 42 to 50 in the last two weeks, and we are only getting started.”
Althea says its aiming to reach 1,000 patients by this time next year and the work they are doing educating mainstream doctors across Australia makes that a “distinct possibility.”
Althea started importing and supplying five co-branded medicinal products to eligible patients in Australia in the form of cannabis oil and dried flower, generating sales revenue starting in May 2018, through a previously announced exclusive supply agreement with Aphria.